Explore Stanford technologies available for licensing:

Researchers at Stanford have developed orthoTeplizumab, an antibody that selectively recognizes engineered T cells without binding a patient's own T cells.

Researchers at Stanford have designed, in silico, a series of new human IL-2 mutants that have biased actions on different immune cell subsets, and confer increased signaling potency compared to natural IL-2.

HIV-1 infection destroys CD4+ T cells and can lead to acquired immunodeficiency syndrome (AIDS).

Stanford researchers have developed recombinant polypeptides targeting growth factor beta (TGF-?) receptor 1 and TGF?

The limited duration of humoral responses to vaccination is a key issue in the fight against infectious diseases, as antibody levels wane over time, leaving individuals vulnerable to reinfection.

Stanford researchers in Dr. Taia Wang's lab have developed a technology that utilizes swainsonine to enhance the cytotoxic potency of monoclonal antibodies, thereby improving their efficacy in cancer and autoimmune disease treatments.

Researchers at Stanford have discovered a therapeutic strategy to overcome off-target red blood cell (RBC) toxicity associated with anti-CD47 antibody cancer therapies and possibly antibody-mediated autoimmune anemia and thrombocytopenia.

Stanford researchers led by Dr.

Stanford scientists have discovered a new immunotherapeutic target for treating lung cancer and fibrotic lung disease.